Olivier Danos - Aug 1, 2024 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
Chief Scientific Officer
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Stock symbol
RGNX
Transactions as of
Aug 1, 2024
Transactions value $
$13,555
Form type
4
Date filed
8/5/2024, 06:38 PM
Previous filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Award $13.6K +1.36K +1.09% $9.95 126K Jun 28, 2024 Direct F1, F2
transaction RGNX Common Stock Award $0 +58.9K +46.64% $0.00 185K Aug 1, 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is exempt under Rule 16b-3(c).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 28, 2024.
F3 Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of February 1, 2025, August 1, 2025, February 1, 2026 and August 1, 2026 while the recipient provides continuous service to the Issuer.